Drug maker Amgen has announced a deal to partner with Simcere Pharmaceutical Group to co-develop and commercialize 4 biosimilar treatments in China.
Drug maker Amgen has announced a deal to partner with Simcere Pharmaceutical Group to co-develop and commercialize 4 biosimilar treatments in China.
Under the agreement, Amgen will be responsible for the co-development, market approval applications, and manufacturing of the biosimilars. Simcere, meanwhile, will distribute and commercialize the drugs in China.
"We are pleased to enter this strategic collaboration with Simcere as we continue to enhance patient access through broader adoption of more competitive therapeutic options worldwide," said Scott Foraker, vice president and general manager of biosimilars at Amgen. "This agreement brings together Amgen's long-standing development and biologics manufacturing expertise with Simcere's local development experience and strong commercial presence in China in the areas of inflammation and oncology.”
While Amgen and Simcere did not disclose the 4 biosimilars included in the deal, Amgen indicated that the drugs are part of its existing biosimilars portfolio. Amgen’s pipeline includes a number of biosimilar candidates: cetuximab, infliximab, rituximab, eculizumab, trastuzumab, and bevacizumab (the newly FDA-approved Mvasi). The company has also gained approval of its biosimilar adalimumab, Amjevita, which will be launched in the United States in 2023 (and in the European Union in 2018 under the name Amgevita) under a new settlement between Amgen and AbbVie, developer of the reference adalimumab, Humira.
China has recently begun to implement significant changes in its regulatory and policy positions on medicines; the China Food and Drug Administration joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)—a not-for-profit entity established under Swiss law to promote international alignment of regulatory authorities—and has tightened its regulation of drugs.
Additionally, in February, the Chinese government updated its list of medicines covered by basic insurance for the first time in 8 years to increase patient access. According to Reuters, patients in China are often forced to resort to “gray markets” to buy cheaper treatments for major illnesses, and the update of the list, which includes 2535 drugs (1297 of them Western drugs) is expected to make high-cost medicines more accessible to the patients who need them. Drugs appearing on the government’s list can be reimbursed up to 80% of their cost.
The Chinese government is also negotiating with drug makers over a confidential list of 45 treatments that have significant therapeutic value but are too expensive for inclusion in the reimbursement scheme. Some analysts suggest that rituximab, trastuzumab, bevacizumab, infliximab, and adalimumab are likely to be on the negotiation list, a scenario that would provide a biosimilar developer with a potential advantage in securing a place on the national formulary.
Switching From Originator Etanercept to Biosimilar Version Proves Safe, Effective in RA
September 5th 2024Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Prioritizing Patient-Centered Care in PsA: Key Insights From the 2023 EULAR Guidelines
August 29th 2024The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care.